Berberine

One of the few supplements that behaves like a drug — including the risks.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In brief: Berberine behaves more like a drug than a supplement. Its glucose- and lipid-lowering effects are real and consistent across meta-analyses, and in one small head-to-head trial its glucose lowering was comparable to that of metformin. The same pharmacological activity inhibits the cytochrome P450 enzymes that clear most prescription drugs, so adding berberine to statins, warfarin, or many cardiovascular and diabetes medications can raise those drugs’ blood levels. No randomized trial has shown that berberine prevents heart attacks, strokes, or cardiovascular death. For anyone taking common cardiovascular or diabetes medications, that interaction profile is the most important information in this article.

Introduction

Berberine occupies an unusual position in the supplement aisle: it is one of very few compounds sold without a prescription that produces metabolic effects in the range of low-dose pharmaceutical therapy.

An alkaloid found in goldenseal, barberry, and Oregon grape, berberine has been used in traditional medicine for centuries. Its modern clinical interest is more specific. Berberine activates AMPK, a cellular energy-sensing enzyme — the same pathway engaged by metformin and by exercise — producing real, reproducible improvements in blood glucose, insulin sensitivity, and blood lipids. Multiple randomized trials and meta-analyses confirm these effects, and in one small head-to-head trial, berberine’s glucose lowering was comparable to metformin over three months. (1,2)

For a supplement, that level of metabolic activity is unusual. It is also the source of the safety concern. Berberine’s pharmacological reach extends to the cytochrome P450 enzyme system — the liver enzymes that metabolize the majority of prescription drugs. (4) In someone taking statins, warfarin, diabetes medications, or many common cardiovascular drugs, berberine can raise those drugs’ blood levels, and for medications with a narrow margin between a helpful dose and a harmful one, that shift can matter.

The cardiovascular case for berberine rests entirely on risk-factor improvement — lower glucose, better lipids — not on outcomes. No randomized trial has tested whether berberine reduces heart attacks, strokes, or cardiovascular death. That gap matters, because the same reasoning — the biomarker improves, so the outcome should improve — has been tested and has failed across several cardiovascular supplement categories. Berberine’s effects are real. Whether they translate into protected cardiovascular outcomes is unknown.

Find Your Situation

The table identifies what the evidence shows for specific clinical profiles. Berberine has no cardiovascular outcome data in any of these situations, so none carries a proven outcome benefit; what changes from row to row is the balance of modest metabolic effect against interaction risk. Each entry is examined in full in the sections that follow.

How Berberine Works

Berberine’s metabolic effects run mainly through AMPK activation — a mechanism it shares with metformin and, to some degree, with exercise.

AMPK activation. AMPK (AMP-activated protein kinase) is a cellular enzyme that acts as an energy sensor. When cellular energy runs low, AMPK switches on a coordinated response: more glucose uptake, more fat burning, less fat and cholesterol synthesis, and improved insulin sensitivity. Berberine activates AMPK in muscle, liver, and fat tissue, driving the glucose and lipid improvements seen in clinical trials. (6,14) Metformin works through a related route — both ultimately reduce the liver’s glucose output and improve insulin sensitivity in peripheral tissue, which is why their short-term glucose effects can look similar.

Glucose metabolism. Beyond those effects on the liver and the insulin response, berberine increases glucose uptake into muscle cells through routes partly independent of insulin, and it slows the absorption of dietary carbohydrate by inhibiting the gut enzymes that break it down. Acting on the liver, the muscle, and the gut at once likely explains why the glucose-lowering is more robust than any single mechanism would predict. (6,14)

Lipid metabolism. Berberine increases LDL receptors in the liver, which pull more LDL out of the bloodstream, and it inhibits cholesterol and triglyceride synthesis. (5) In cell studies it also lowers PCSK9, a protein that breaks down LDL receptors; reducing PCSK9 leaves more receptors available to clear LDL. (12) This is the same protein targeted by injectable PCSK9-inhibitor antibodies, though berberine reduces PCSK9 production rather than blocking the circulating protein, and its effect is far smaller and demonstrated mainly in the laboratory. The lipid mechanism is distinct from statins, which in principle could make the two additive — but the interaction profile described below turns that combination into a clinical question rather than a simple option.

Bioavailability and gut effects. Less than 1% of an oral dose of berberine reaches the bloodstream intact; most is metabolized in the gut wall or never absorbed. Much of its metabolic effect may therefore occur in the gut itself, where berberine substantially alters the bacterial community, and these microbiome changes may contribute meaningfully to its clinical effects. (7) This is an active research area, and it may explain why berberine’s clinical effects exceed what its very low absorption into the circulation would predict.

The same pharmacological activity that drives these metabolic effects also reaches the cytochrome P450 enzyme system — the basis for berberine’s drug interaction profile, covered in full below.

The Clinical Evidence

Glucose Lowering: What the Trials Show

The glucose-lowering evidence is more substantial than for most supplements, though it falls short of pharmaceutical-grade standards in sample size, population diversity, and follow-up. The signal, however, is consistent.

The most-cited comparison is Yin 2008, which randomized 36 adults with newly diagnosed type 2 diabetes to either berberine (500 mg three times daily) or metformin (500 mg three times daily) for three months. (1) The headline finding — comparable glucose lowering — is real, but the trial is small enough that it should be read as hypothesis-generating rather than definitive.

The glucose reductions were statistically comparable to metformin’s; berberine additionally lowered triglycerides, an effect metformin did not match in this trial. (1)

Larger pooled data point in the same direction. A 2015 meta-analysis of 27 randomized trials with 2,569 participants found that berberine — alone or added to standard therapy — significantly lowered fasting glucose, HbA1c, and LDL cholesterol, and other systematic reviews report the same pattern. (2,3) Across these analyses, the HbA1c reduction falls roughly in the range of 0.5 to 0.7 percentage points; the exact pooled figures vary from one analysis to the next, reflecting differences in the populations studied and the quality of the underlying trials. Most berberine trials are short, conducted primarily in Chinese populations, and of modest methodological quality, so how well the results generalize is uncertain.

An HbA1c reduction in that range is in the territory of metformin’s typical effect and smaller than that of SGLT2 inhibitors or GLP-1 agonists at standard doses. But the decisive issue is not the effect size — it is the evidence context. Metformin has cardiovascular outcome data: in overweight patients with type 2 diabetes, it reduced diabetes-related events and all-cause mortality in the UKPDS trial. (10) SGLT2 inhibitors and GLP-1 agonists have robust outcome data showing fewer major cardiovascular events, fewer heart-failure hospitalizations, and lower mortality in high-risk groups. Berberine has no comparable outcome data. The metabolic numbers are real; the clinical protection is unproven.

Lipid Effects: Where Berberine Sits

Berberine lowers LDL and triglycerides through mechanisms distinct from statins. The table below places its effects in approximate context against established lipid therapies; the berberine figures come from trials enriched for abnormal cholesterol (dyslipidemia) and should be read as a general range, not a precise expectation. (2,9)

Berberine’s lipid effects exceed most supplements and approach low-dose-statin territory, which is clinically meaningful in moderate dyslipidemia, particularly given a mechanism distinct from statins. The essential caveat holds: statins have decades of cardiovascular outcome data across more than 170,000 patients in independent trials. (9) Berberine’s lipid reductions have not been shown to reduce cardiovascular events.

The Outcome Data That Does Not Exist

Across berberine’s entire evidence base, the same gap applies: no large randomized trial has tested whether it reduces heart attacks, strokes, or cardiovascular death.

The benefit is inferred — berberine lowers glucose and LDL; lower glucose and LDL reduce cardiovascular events; therefore berberine should reduce events. That chain is biologically plausible, and it is exactly the reasoning that cardiovascular medicine has tested before and seen fail. Niacin raised HDL and improved several risk markers just as predicted, and two large outcome trials found no benefit and signals of harm. Antioxidant vitamins improved markers of oxidative stress just as predicted and did not reduce events. Folic acid and B vitamins lowered homocysteine just as predicted and did not reduce events.

Berberine’s metabolic effects are more compelling than any of those. That makes the missing outcome trial a larger gap, not a smaller one — because the more convincing the biomarker data, the easier it is to assume the outcome question has already been answered when it has not. There is also an economic reason the trial does not exist. Large cardiovascular outcome trials cost hundreds of millions of dollars and take years; they are typically funded by companies with a patent-protected product whose sales can recoup the investment. Berberine is a low-cost generic with no patent position, so the commercial incentive to fund that trial is absent. The point is not that the evidence would turn out favorable if only someone paid for it — that is exactly the assumption this section warns against. It is that the outcome question remains open, for reasons that have more to do with economics than with science.

Berberine and Cardiovascular Guidelines

No major cardiovascular or diabetes guideline recommends berberine.

The American Diabetes Association Standards of Care, the European Association for the Study of Diabetes consensus statements, the 2018 ACC/AHA cholesterol guideline, the 2017 ACC/AHA hypertension guideline, and the 2022 AHA/ACC/HFSA heart failure guideline do not include berberine as recommended therapy for any cardiovascular or metabolic indication. Metformin, SGLT2 inhibitors, GLP-1 agonists, statins, ACE inhibitors, and ARBs all carry guideline-level recommendations supported by outcome-trial evidence. Berberine has biomarker-level evidence and no outcome trials, and the guidelines reflect that distinction precisely.

What this means: Berberine is not part of any current cardiovascular or diabetes guideline. The case for it rests on biomarker improvement and pharmacological inference — not on the outcome evidence those guidelines require.

Drug Interactions: The Central Safety Concern

Berberine’s metabolic potency and its interaction risk come from the same source: it is pharmacologically active in ways most supplement labels do not communicate.

Berberine inhibits the drug-metabolizing enzymes CYP3A4, CYP2D6, and CYP2C9. (4) It also inhibits P-glycoprotein, a transport protein that limits how much of a drug enters cells, which adds to its interaction potential. CYP3A4 alone handles roughly half of all prescription drugs. (11) When berberine slows these pathways, drugs that would normally be metabolized and cleared can instead accumulate, raising blood levels in ways a prescriber did not intend and may not know about.

The human evidence is direct, and it is worth being precise about its size. In a controlled crossover study in healthy volunteers, two weeks of berberine at 900 mg per day — within the range people take for metabolic effects — measurably reduced the activity of three of these enzymes. The effect on CYP2D6 was strong. The effects on CYP2C9 and CYP3A4 were more moderate: a standard CYP3A4 probe drug’s blood levels rose by about 40%. (4) For many medications, a 40% increase is clinically modest. But for drugs with a narrow margin between a therapeutic and a toxic dose — warfarin, certain statins near their muscle-injury threshold, immunosuppressants, some heart-rhythm and psychiatric drugs — even a moderate change can have consequences, and the effect adds to other inhibitors and varies between individuals. The risk is best understood not as a guarantee of harm but as a real, predictable shift — one that matters most for the drugs that tolerate it least.

Statins. Simvastatin, lovastatin, and atorvastatin are extensively metabolized by CYP3A4, so berberine can raise their blood levels and increase the risk of myopathy — muscle inflammation and breakdown. (4) Rosuvastatin is only minimally handled by CYP3A4 and carries a lower interaction risk by this route, though other mechanisms have not been fully characterized. Rhabdomyolysis, the severe form of statin myopathy, can cause kidney failure. This interaction matters especially because the people most likely to consider berberine for cholesterol may already be taking one of these statins.

Warfarin. Metabolized by CYP2C9, warfarin has one of the narrowest therapeutic windows of any common drug. Small changes in its metabolism push the INR — the test of how quickly blood clots — out of the safe range: too high risks bleeding, too low risks clots. Berberine can raise warfarin’s effect. (4)

Diabetes medications. Adding berberine’s glucose lowering to metformin, sulfonylureas, insulin, or SGLT2 inhibitors produces additive reduction and a real risk of hypoglycemia — low blood sugar — which can range from unpleasant to dangerous. (1,2)

Calcium channel blockers. Several common blood pressure medications — amlodipine, nifedipine, diltiazem, verapamil — are CYP3A4 substrates, and berberine can raise their levels, lowering blood pressure more than intended. (4)

Immunosuppressants. Cyclosporine and tacrolimus, used after organ transplantation, have narrow therapeutic windows: the gap between too little (allowing rejection) and too much (causing toxicity) is small. In a clinical study of kidney transplant recipients, berberine raised cyclosporine blood levels, confirming in humans what the CYP3A4 mechanism predicts. (13)

Psychiatric medications. Many antidepressants and antipsychotics are CYP2D6 substrates — the enzyme berberine inhibits most strongly — so berberine can raise their levels and amplify side effects. (4)

The pattern across all of these is the same: the interaction is usually silent until a clinical consequence makes it visible. Statin myopathy may begin as fatigue or vague muscle aches that are easy to attribute elsewhere. A warfarin interaction may surface only when INR testing reveals it. Hypoglycemia may be mild and unrecognized. And many clinicians never learn the interaction exists, because supplement use is routinely left off medication lists during visits, admissions, and emergency care, and most clinicians do not ask specifically. These interactions are predictable and manageable when known — and invisible when not disclosed.

Other Safety Considerations

Gastrointestinal effects. Cramping, diarrhea, constipation, nausea, and abdominal pain are the most common adverse effects, affecting a meaningful minority of users in trials. (1,2) Starting at a lower dose and increasing gradually is the usual way to reduce them.

Hypoglycemia. Berberine’s glucose lowering creates a real risk of low blood sugar when it is combined with diabetes medications, or in people who are fasting or under-eating. Symptoms — shakiness, sweating, confusion, rapid heartbeat — range from mild to severe. (1,2)

Pregnancy and breastfeeding. Berberine is generally advised against during pregnancy and breastfeeding. The specific concern in newborns is that it can displace bilirubin — a yellow pigment from the normal breakdown of red blood cells — from the blood proteins that carry it, which can worsen jaundice. (8) That risk, together with the absence of safety data in pregnancy, is the basis for the standard caution.

Long-term safety. Most studies are short. Long-term safety data are limited, and whether sustained use produces problems that brief trials would miss is not yet known. (2)

Dosing and Product Quality

Most trials use 500 mg two to three times daily — 1,000 to 1,500 mg total — taken with or shortly before meals. (1,2) Berberine clears from the body relatively quickly and only a small fraction of a dose is absorbed, so dividing the dose across the day maintains steadier levels than a single large dose. (7)

Berberine HCl (hydrochloride) is the most-studied form. Some products claim enhanced absorption, but clinical evidence that they outperform standard berberine HCl is limited. Independent third-party verification — USP Verified or NSF International certification, or testing by a service such as ConsumerLab — provides reasonable assurance of identity, potency, and purity, which matters more here than for a less pharmacologically active supplement, because berberine’s interaction profile makes dose accuracy clinically relevant.

Two Patients, Same Supplement Aisle, Different Answers

Both profiles below are composites, built from the populations studied in the trials this article reviews.

Patient A: A 51-year-old woman with prediabetes — fasting glucose 112 mg/dL, HbA1c 6.1% — and mildly elevated LDL at 138 mg/dL. She takes no prescription medications, exercises regularly, and is working on her diet. She asks whether berberine would help her metabolic profile.

She is among the patients for whom berberine’s evidence is most applicable and its interaction risk lowest: no interacting medications, and exactly the metabolic markers berberine’s trials have targeted. The realistic expectation is a modest improvement in biomarkers — an HbA1c reduction in the range trials report, and some LDL lowering — not a demonstrated reduction in cardiovascular events, which has never been tested for berberine. (1,2) Gastrointestinal effects are common early on, and because berberine inhibits CYP450 enzymes, any prescription medication she starts in the future would carry an interaction to consider. Whether berberine fits her situation is a question her physician is positioned to weigh with full context; the evidence picture here is more favorable than for most people who consider this supplement, but it remains a biomarker case, not an outcome one.

Patient B: A 67-year-old man with type 2 diabetes on metformin and glipizide (a sulfonylurea), and established coronary artery disease, on atorvastatin, aspirin, and an ACE inhibitor. He reads about berberine’s glucose lowering and considers adding it to his regimen.

He has several significant interactions at once. Berberine added to glipizide and metformin produces additive glucose lowering with a documented risk of hypoglycemia. (1,2) Berberine added to atorvastatin can raise the statin’s blood level through CYP3A4 inhibition, increasing the risk of muscle injury. (4) He has established cardiovascular disease, where berberine has no outcome evidence, while the therapies already in place have cardiovascular benefit proven in large trials. (9,10) For him, the interaction profile combined with the absence of outcome evidence is precisely the information his prescribing physician would need to weigh before anything is added to the regimen.

Common Misconceptions

“Berberine is nature’s metformin.” The comparison has real biological traction, which is why it has spread so widely. Both activate AMPK, both reduce the liver’s glucose output between meals, and both improve insulin sensitivity in peripheral tissue. In the Yin 2008 trial, berberine produced an HbA1c reduction comparable to metformin’s over three months in 36 patients. (1) Those facts are real. What the slogan strips away is everything that makes them an insufficient basis for equivalence: that trial ran three months in 36 people; metformin has been studied in millions over six decades with well-characterized long-term safety; metformin has cardiovascular outcome evidence from UKPDS; (10) and metformin does not inhibit cytochrome P450 enzymes, so it does not carry berberine’s interaction profile. Two compounds can share a mechanism and similar short-term biomarker effects while differing completely in safety, evidence depth, and clinical context. The AMPK overlap is why the comparison sounds credible; the rest of the evidence is why it does not hold.

“Berberine is safe because it’s a plant compound.” Plant origin is not a safety argument. Many of the most potent drugs in pharmacology are plant-derived. Berberine’s CYP450 inhibition affects the same enzymes that pharmaceutical drug-interaction warnings are built around. (4) Pharmacology determines the safety profile, not botanical origin.

“If berberine lowers cholesterol and glucose, it must reduce cardiovascular events.” Lower glucose and LDL generally do reduce cardiovascular risk — but that translation has been demonstrated for specific therapies sustained over years, not assumed from biomarkers. Niacin raised HDL and improved cholesterol-related markers and still failed to reduce events in two large trials. The step from biomarker improvement to outcome benefit is not automatic, and for berberine it has not been tested.

“Berberine doesn’t interact with my medications — it’s not a drug.” Berberine inhibits CYP3A4, CYP2D6, and CYP2C9 (4), and it also inhibits the P-glycoprotein transporter. These are the same enzymes and transport proteins clinical pharmacists screen when checking for drug interactions. The label “supplement” does not change the underlying pharmacology.

“CYP450 interactions are theoretical — I’d notice if something was wrong.” Many of these interactions develop gradually and present without specific symptoms. Statin myopathy may begin as fatigue or vague muscle discomfort. Warfarin accumulation may be silent until an INR test or a bleeding event reveals it. Hypoglycemia from additive glucose lowering can be mild and easy to attribute to a missed meal. The interactions are predictable and manageable — but only when disclosed.

“There’s nothing to lose by trying berberine.” For a pharmacologically active compound with documented CYP450 inhibition, starting it alongside common cardiovascular or diabetes medications without a prescriber’s knowledge creates an unmonitored interaction. The first sign of that interaction may be a clinical event — muscle injury, a bleeding episode, or a hypoglycemic one — rather than a gradual warning.

The Bottom Line

Berberine’s metabolic effects are more compelling than almost any supplement in this series. Its interaction profile is more consequential than almost any supplement in this series. And its cardiovascular outcome evidence is exactly as absent as every other supplement covered here. Those three facts together decide whether berberine belongs in any individual’s regimen, and the weight each carries depends entirely on that person’s medication list, metabolic status, and clinical context.

The evidence picture differs sharply depending on who is reading. For someone with prediabetes or metabolic syndrome and no interacting medications, berberine has more trial support than most supplements here — real metabolic effects, a mechanism that makes biological sense, and an interaction profile that is manageable when no interacting drugs are in the picture. For someone already on simvastatin, lovastatin, atorvastatin, warfarin, diabetes medications, or immunosuppressants, the pharmacology is not ambiguous: berberine can raise those drugs’ blood levels through CYP450 inhibition, and the possible consequences — muscle injury, bleeding, hypoglycemia, transplant rejection — are serious enough that a prescriber would need to know before berberine enters the regimen. For someone with established cardiovascular disease already on evidence-based therapy, berberine adds interaction risk to a regimen built on drugs whose cardiovascular benefit has been proven in large trials, while berberine’s own cardiovascular benefit has not been tested at all.

The distinction that governs every berberine decision is the one that runs through this entire series: a supplement that improves a measurement is not the same as a therapy that reduces events. For berberine, the first is better demonstrated than for almost any supplement covered here. The second has not been tested.

Article 14 turns to vitamin K2 — a supplement with mechanistically interesting calcification biology, enthusiastic marketing, and a randomized trial that found no reduction in calcification progression.

Key Terms

AMPK (AMP-activated protein kinase): A cellular enzyme that acts as a metabolic master switch, activated when cellular energy is low. Berberine activates AMPK in muscle, liver, and fat tissue — the same pathway used by metformin and by exercise — improving glucose uptake, fat metabolism, and insulin sensitivity.

Berberine: An alkaloid found in plants including goldenseal, barberry, and Oregon grape. Produces meaningful metabolic effects through AMPK activation and other pathways, and inhibits multiple CYP450 enzymes, creating clinically significant drug-interaction potential.

Cytochrome P450 (CYP450): A family of liver enzymes that metabolize the majority of prescription drugs. Berberine inhibits CYP3A4, CYP2D6, and CYP2C9, which can raise the blood levels of co-administered drugs — a particular concern for medications with a narrow margin between a therapeutic and a toxic dose.

HbA1c: Glycated hemoglobin, reflecting average blood glucose over roughly two to three months. A standard marker of diabetes control. Berberine reduces HbA1c by roughly 0.5 to 0.7 percentage points across meta-analyses — a modest but meaningful change.

Metabolic syndrome: A cluster of conditions — abdominal obesity, elevated triglycerides, low HDL, elevated blood pressure, elevated fasting glucose — that together raise cardiovascular risk. Berberine has shown effects on several components at once in trial data.

Myopathy: Muscle inflammation and breakdown, the main serious adverse effect of statins. When berberine raises statin blood levels through CYP3A4 inhibition, the risk of myopathy increases. Rhabdomyolysis — severe myopathy with kidney injury — is the most serious form.

P-glycoprotein: A transport protein in cell membranes that pumps drugs out of cells, limiting their absorption and tissue entry. Berberine inhibits it, adding to its drug-interaction profile alongside CYP450 inhibition.

PCSK9: A protein that breaks down LDL receptors in the liver, reducing the liver’s capacity to clear LDL from the blood. Berberine lowers PCSK9 expression in cell studies — the same protein targeted by injectable PCSK9-inhibitor antibodies, though by a different route and with a far smaller effect.

References

1. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717.
2. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
3. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654.
4. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217.
5. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–1351.
6. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–2565.
7. Cicero AF, Baggioni A. Berberine and its role in chronic disease. Adv Exp Med Biol. 2016;928:27–45.
8. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201–208.
9. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
11. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141.
12. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201(2):266–273.
13. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567–572.
14. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–2264.

HeartBuddi • Your heart. Own it.